Company Overview and News
2018-10-17 rigzone - 1
(Bloomberg) -- BP Plc’s new U.S. onshore oil headquarters in Denver serves as a testament to Colorado’s regal mountains, its expansive forests, its nature-loving culture.
APC BP UPL NBL BP UPLMQ BPAQF BP.A AEUA BP.B
ConocoPhillips (NYSE:COP) has a major understated presence in Alaska. As a source of roughly half a million barrels per day of conventional oil production, Alaska’s upstream sector is highly profitable. During the worst of the 2014-2017 downturn, ConocoPhillips still churned out $4 million in net income from its Alaskan division in 2015 and $319 million in 2016. That grew to $1.466 billion last year, which is better put as an adjusted $684 million (excluding major tax benefits and impairment charges).
COP APC BP AEUA
* Tohoku Electric Power Co said it had signed the first contract by a Japanese buyer to procure up to 280,000 tonnes per year of liquefied natural gas (LNG) from Mozambique LNG project for 15 years from the start of production in the early 2020s.
HOUSTON (Reuters) - U.S. Gulf of Mexico producers have cut oil output by 32 percent and natural gas production by 18 percent as a result of the lingering effects of Hurricane Michael, the Bureau of Safety and Environmental Enforcement (BSEE) said on Friday, citing reports from 27 companies.
APC BLT XOM BHPBF BP BP.A BP.B BP BHP CVX BBL BHP BPAQF BHPLF AEUA
HOUSTON (Reuters) - Major oil producers and drillers, including Chevron Corp (CVX.N) and BP Plc (BP.L), on Thursday began returning crews to more than 90 offshore facilities in the U.S. Gulf of Mexico that were evacuated this week as Hurricane Michael moved through the Gulf.
SOJA SO APC BP CVX BP BPAQF BP.A AEUA BP.B
HOUSTON (Reuters) - Oil producers on Thursday were checking Gulf of Mexico production platforms and beginning to return crews to more than 90 offshore facilities evacuated this week as Hurricane Michael moved through the Gulf.
SOJA APC SO BP BP BPAQF AEUA BP.A BP.B
(Bloomberg) -- Higher oil prices may seem like the pot of black gold at the end of the rainbow for wildcat explorers in frontier plays. But even with talk that prices of $100 a barrel could again be in sight, investors are wary before taking the gamble.
APC BP XOM CIEIQ BP BPAQF BP.A AEUA CIE BP.B
HOUSTON (Reuters) - Hurricane Michael on Wednesday cut 42 percent of U.S. Gulf of Mexico daily crude oil production and nearly a third of natural gas output, the largest reductions in a year, after companies evacuated staff and shut-in platforms as a precaution.
SOJA SO APC BLT XOM BHPBF KMI BHP CVX BBL BHP KMR BHPLF CVB AEUA KMRFZ
HOUSTON (Reuters) - U.S. Gulf of Mexico producers have cut daily oil production by roughly 42 percent and natural gas output by nearly 32 percent due to Hurricane Michael, the Bureau of Safety and Environmental Enforcement said on Wednesday, citing reports from 30 companies.
APC BLT XOM BHPBF BP BP.A BP.B BP BHP BBL BHP BPAQF BHPLF AEUA
HOUSTON, Oct 8 (Reuters) - Anadarko Petroleum Corp on Monday shut its Marlin and Horn Mountain oil and gas platforms in the U.S. Gulf of Mexico and evacuated staff ahead of Hurricane Michael, the company said.
APC BLT BHP XOM BHPBF BBL BHP BHPLF AEUA
ConocoPhillips (COP - Free Report) announced a quarterly dividend of 30.5 cents per share, up 7% from 28.5 cents on a sequential basis. The uptick marks the second hike by the company in the current year. The dividend is payable on Dec 3, 2018, to stockholders of record at the close of business as of Oct 15, 2018. The first hike was announced in February, when ConocoPhillips declared a dividend of 28.
COP APC KMI KMR KMRFZ AEUA CVB
2018-10-08 seekingalpha - 5
E&P companies that are neither top institutional favorites nor companies I would classify in my Bottom of the Barrel Club may have wide appeal to investors.
GIS XOM PXD QEP AR CRZO WMB XOG NBL WLL PDCE SRCI SM CTLR NFX RRS WPX ESTE RGRLF RRC WTI CLR OXY AEUA HAL APC APA WPXP DVN CXO PE RRL COP ROSEU RSPP REI AMR EGN JAG ROSE CDEV D COG EOG RGRYY HP CVX LPI HK FANG
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET